CAS NO: | 2309699-17-8 |
包装 | 价格(元) |
10 mM * 1 mL in DMSO | 电议 |
2mg | 电议 |
5mg | 电议 |
10mg | 电议 |
50mg | 电议 |
100mg | 电议 |
200mg | 电议 |
500mg | 电议 |
生物活性 | Mavorixafor trihydrochloride (AMD-070 trihydrochloride) is a potent, selective and orally availableCXCR4antagonist, with anIC50value of 13 nM againstCXCR4125I-SDF binding, and also inhibits the replication of T-tropicHIV-1(NL4.3 strain) in MT-4 cells and PBMCs with anIC50of 1 and 9 nM, respectively. | ||||||||||||||||
IC50& Target[1] |
| ||||||||||||||||
体外研究 (In Vitro) | Mavorixafor (AMD-070) is a potent and orally available CXCR4 antagonist, with an IC50value of 13 nM against CXCR4125I-SDF binding, and also inhibits the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs with an IC50of 1 and 9 nM, respectively. Mavorixafor (AMD-070) shows no effect on other chemokine receptors (CCR1, CCR2b, CCR4, CCR5, CXCR1, and CXCR2)[1]. Mavorixafor (AMD-070) (6.6 μM) significantly suppresses the anchorage-dependent growth, the migration and matrigel invasion of the B88-SDF-1 cells[2]. | ||||||||||||||||
体内研究 (In Vivo) | Mavorixafor (AMD-070) (2 mg/kg, p.o.) significantly reduces the number of metastatic lung nodules in mice, and lowers the expression of human Alu DNA in mice, without body weight loss[2]. | ||||||||||||||||
Clinical Trial | |||||||||||||||||
分子量 | 458.86 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C21H30Cl3N5 | ||||||||||||||||
CAS 号 | 2309699-17-8 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 | 4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) | ||||||||||||||||
溶解性数据 | In Vitro: DMSO : 150 mg/mL(326.90 mM;Need ultrasonic) H2O : 100 mg/mL(217.93 mM;Need ultrasonic) 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|